^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
Plasma-SeqSensei™ Solid Cancer IVD Kit

Company:
Sysmex Corp
Type:
CE Marked
Related tests:

Details

Evidence
Plasma-SeqSensei™ (PSS) assays enable highly sensitive and quantitative detection of mutations in circulating tumour DNA (ctDNA) from the blood plasma of cancer patients by utilising next-generation sequencing technology. PSS's short and standardised workflow delivers results within two days including the generation of easy-to-read reports using laptop-compatible Plasma-SeqSensei™ IVD Software. PSS Solid Cancer IVD Kit is intended to support clinicians with detecting minimal residual disease; recurrence surveillance; (neo-)adjuvant response monitoring; and analysing the RAS mutation status to determine the potential benefit of anti-epidermal growth factor receptor (EGFR) therapy for colorectal cancer patients.
Cancer:
Solid Tumor
Gene:
BRAF (B-raf proto-oncogene), EGFR (Epidermal growth factor receptor), KRAS (KRAS proto-oncogene GTPase), NRAS (Neuroblastoma RAS viral oncogene homolog), PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
Method:
Next-Generation Sequencing (NGS) / Circulating tumor DNA (ctDNA)
Approvals
Date
Cancer
Gene
Drug
By
05/25/22
CE